The Biden administration announced Thursday that drug companies receiving research funding from HHS’ emergency response arm, the Administration for Strategic Preparedness and Response, will have to commit to a “fair price” – not more than they charge in other countries. Host Chelsea Cirruzzo talks with POLITICO health care reporter Robert King about the Biden administration's efforts to curb high prescription drug prices.
The start of the FDA's pivot in immunization strategy
Inside Amazon's new prescription subscription
Lawsuit asks whether social media companies are responsible for mental health issue
In conservative states, anti-abortion groups butt heads with ... Republicans
What Zients' stint as Covid czar tells us about what kind of chief of staff he'll be
This is what’s keeping pharmacy shelves bare
GAO questions HHS oversight of ‘gain-of-function’ research
Democratic Sen. Warner pushes for health cybersecurity legislation
The Biden admin's big plans for airplane toilets
Inside the crisis in the U.K.'s National Health Service
The end of the covid public health emergency could limit virtual prescribing
What Maine’s prisons taught Washington about fighting opioids
Biden navigates the end of the Covid public health emergency
The fight over how to deliver bad news to patients
FDA approves second Alzheimer’s treatment
The state of mental health and substance use in the U.S.
The latest on XBB.1.5
Anti-abortion groups give House GOP a list of their demands
What's next on the AI front in health care
What we learned from the mpox outbreak
Create your
podcast in
minutes
It is Free